BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies
Work
Year: 2020
Type: article
Abstract: PURPOSE For immunotherapy, such as checkpoint inhibitors and chimeric antigen receptor T-cell therapy, where the efficacy does not necessarily increase with the dose, the maximum tolerated dose may no... more
Source: JCO Precision Oncology
Institutions The University of Texas MD Anderson Cancer Center, China Pharmaceutical University, Bristol-Myers Squibb (United States)
Cites: 42
Cited by: 98
Related to: 10
FWCI: 8.347
Citation percentile (by year/subfield): 73.35
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Sustainable Development Goal Partnerships for the goals
Open Access status: bronze